Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Scientists Describe New Herpes Treatment Strategy

By R&D Editors | December 3, 2014

Herpes simplex virus. (Credit: CDC)Scientists have developed a novel treatment approach for persistent viral infections such as herpes.
 
Using animal models of herpes simplex virus (HSV) infection, researchers show that blocking the activity of a host cell protein called LSD1 reduces HSV infection, shedding (release of viral particles) and recurrence. LSD1, which is essential for HSV’s infectious cycle, modifies certain host proteins that control access to DNA. These modifications, known as “epigenetic” changes, help determine how and when genes are used. The collaborative effort, led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, demonstrates the potential of epigenetic therapy as an antiviral strategy.
 
After initial infection, HSV enters a latent state in sensory nerve cells, periodically reactivating to produce disease. HSV typically causes recurrent oral or genital lesions and can contribute to the eye disease herpetic keratitis, a leading cause of blindness. Even without symptoms, HSV-infected people can shed and transmit the virus. Current HSV treatments, which target viral proteins, do not effectively control shedding or reactivation of latent virus.
 
The investigators used an existing drug, tranylcypromine, to block LSD1 activity in three different animal models of HSV infection and disease. The treatment targets a very early stage of the HSV infectious cycle and greatly reduced symptoms of HSV disease, shedding and lesion recurrence. By blocking a cellular rather than viral component, the treatment may minimize the evolution of drug-resistant viruses.
 
The results also indicate that even during latency, HSV’s genetic material is subject to epigenetic changes that can be regulated with drugs. Epigenetic therapies are rapidly being developed as cancer treatments, opening the possibility to also test these drugs for antiviral activity.
 
Source: NIH

Related Articles Read More >

Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
Waters touts six-fold robustness with new Xevo TQ Absolute XR
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE